| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.008 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.16 | 0.008 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.008 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |